Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned
Other Lilly and NIH Studies Continue
Executive Summary
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
You may also be interested in...
Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.
Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
Digital Scrip Awards Celebrate Biopharma After An Exceptional Year
The big winners of the night were AstraZeneca and Roche as pharma, biotech and allied industries came together online on 2 December to celebrate during a ceremony hosted by Ed Balls.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports